Compare Anheuser-Busch Inbev SA (BUD) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Eli Lilly And Co — how do they compare? Anheuser-Busch Inbev SA trades at $78.88 (market cap $153.45B), while Eli Lilly And Co trades at $1,148 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 6.7× Anheuser-Busch Inbev SA's market cap, and Anheuser-Busch Inbev SA pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| BUD | LLY | |
|---|---|---|
Market Cap | $153.45B | $1.03T |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $1.24K |
52-Week Low | $57.10 | $625.65 |
Enterprise Value | $214.64B | $1.07T |
Dividend Yield | 1.7% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
